Sienna Cancer Diagnostics Ltd. continues its global expansion, signing a new distributor for South Korea. The distribution agreement provides Mirax Corporation, Ltd. with the right to sell Sienna's product to Korean pathology laboratories, where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer. This is the second Asian distributor for the Company, with its hTERT in-vitro diagnostic (IVD) test already assigned to distributors in the US, Denmark, Sweden, Switzerland, and recently mainland China. The Republic of Korea presents a substantial market opportunity for Sienna with over 300,000 urine cytology tests believed to be performed annually. The appointment follows an evaluation process involving several high-quality candidates. Sienna, in collaboration with Mirax, will now seek to gain regulatory approval in the Republic of Korea.